Human CACNA1D/CACH3/CACN4 ORF/cDNA clone-Adenovirus particle (NM_001128839.3)

Cat. No.: vGMAD001198

Pre-made Human CACNA1D/CACH3/CACN4 Adenovirus for CACNA1D overexpression in-vitro and in-vivo. The CACNA1D adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified CACNA1D-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.

At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.

Target products collection

Go to CACNA1D/CACH3 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name Adenovirus Grade Adenovirus quantity
vGMAD001198 Human CACNA1D Adenovirus particle Research Grade-In vitro 1E+10PFU (1E+10pfu/ml×1ml)
5E+10PFU (1E+10pfu/ml×5ml)
1E+11PFU (1E+10pfu/ml×10ml)
Research Grade-In vivo 1E+11PFU (1E+11pfu/ml×1ml)
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMAD001198
Gene Name CACNA1D
Accession Number NM_001128839.3
Gene ID 776
Species Human
Product Type Adenovirus particle (overexpression)
Insert Length 6414 bp
Gene Alias CACH3,CACN4,CACNL1A2,Cav1.3,CCHL1A2,PASNA,SANDD
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag Null
Promoter EF1
Resistance Kanamycin
ORF Nucleotide Sequence ATGATGATGATGATGATGATGAAAAAAATGCAGCATCAACGGCAGCAGCAAGCGGACCACGCGAACGAGGCAAACTATGCAAGAGGCACCAGACTTCCTCTTTCTGGTGAAGGACCAACTTCTCAGCCGAATAGCTCCAAGCAAACTGTCCTGTCTTGGCAAGCTGCAATCGATGCTGCTAGACAGGCCAAGGCTGCCCAAACTATGAGCACCTCTGCACCCCCACCTGTAGGATCTCTCTCCCAAAGAAAACGTCAGCAATACGCCAAGAGCAAAAAACAGGGTAACTCGTCCAACAGCCGACCTGCCCGCGCCCTTTTCTGTTTATCACTCAATAACCCCATCCGAAGAGCCTGCATTAGTATAGTGGAATGGAAACCATTTGACATATTTATATTATTGGCTATTTTTGCCAATTGTGTGGCCTTAGCTATTTACATCCCATTCCCTGAAGATGATTCTAATTCAACAAATCATAACTTGGAAAAAGTAGAATATGCCTTCCTGATTATTTTTACAGTCGAGACATTTTTGAAGATTATAGCGTATGGATTATTGCTACATCCTAATGCTTATGTTAGGAATGGATGGAATTTACTGGATTTTGTTATAGTAATAGTAGGATTGTTTAGTGTAATTTTGGAACAATTAACCAAAGAAACAGAAGGCGGGAACCACTCAAGCGGCAAATCTGGAGGCTTTGATGTCAAAGCCCTCCGTGCCTTTCGAGTGTTGCGACCACTTCGACTAGTGTCAGGAGTGCCCAGTTTACAAGTTGTCCTGAACTCCATTATAAAAGCCATGGTTCCCCTCCTTCACATAGCCCTTTTGGTATTATTTGTAATCATAATCTATGCTATTATAGGATTGGAACTTTTTATTGGAAAAATGCACAAAACATGTTTTTTTGCTGACTCAGATATCGTAGCTGAAGAGGACCCAGCTCCATGTGCGTTCTCAGGGAATGGACGCCAGTGTACTGCCAATGGCACGGAATGTAGGAGTGGCTGGGTTGGCCCGAACGGAGGCATCACCAACTTTGATAACTTTGCCTTTGCCATGCTTACTGTGTTTCAGTGCATCACCATGGAGGGCTGGACAGATGTGCTCTACTGGATGAATGATGCTATGGGATTTGAATTGCCCTGGGTGTATTTTGTCAGTCTCGTCATCTTTGGGTCATTTTTCGTACTAAATCTTGTACTTGGTGTATTGAGCGGAGAATTCTCAAAGGAAAGAGAGAAGGCAAAAGCACGGGGAGATTTCCAGAAGCTCCGGGAGAAGCAGCAGCTGGAGGAGGATCTAAAGGGCTACTTGGATTGGATCACCCAAGCTGAGGACATCGATCCGGAGAATGAGGAAGAAGGAGGAGAGGAAGGCAAACGAAATACTAGCATGCCCACCAGCGAGACTGAGTCTGTGAACACAGAGAACGTCAGCGGTGAAGGCGAGAACCGAGGCTGCTGTGGAAGTCTCTGTCAAGCCATCTCAAAATCCAAACTCAGCCGACGCTGGCGTCGCTGGAACCGATTCAATCGCAGAAGATGTAGGGCCGCCGTGAAGTCTGTCACGTTTTACTGGCTGGTTATCGTCCTGGTGTTTCTGAACACCTTAACCATTTCCTCTGAGCACTACAATCAGCCAGATTGGTTGACACAGATTCAAGATATTGCCAACAAAGTCCTCTTGGCTCTGTTCACCTGCGAGATGCTGGTAAAAATGTACAGCTTGGGCCTCCAAGCATATTTCGTCTCTCTTTTCAACCGGTTTGATTGCTTCGTGGTGTGTGGTGGAATCACTGAGACGATCTTGGTGGAACTGGAAATCATGTCTCCCCTGGGGATCTCTGTGTTTCGGTGTGTGCGCCTCTTAAGAATCTTCAAAGTGACCAGGCACTGGACTTCCCTGAGCAACTTAGTGGCATCCTTATTAAACTCCATGAAGTCCATCGCTTCGCTGTTGCTTCTGCTTTTTCTCTTCATTATCATCTTTTCCTTGCTTGGGATGCAGCTGTTTGGCGGCAAGTTTAATTTTGATGAAACGCAAACCAAGCGGAGCACCTTTGACAATTTCCCTCAAGCACTTCTCACAGTGTTCCAGATCCTGACAGGCGAAGACTGGAATGCTGTGATGTACGATGGCATCATGGCTTACGGGGGCCCATCCTCTTCAGGAATGATCGTCTGCATCTACTTCATCATCCTCTTCATTTGTGGTAACTATATTCTACTGAATGTCTTCTTGGCCATCGCTGTAGACAATTTGGCTGATGCTGAAAGTCTGAACACTGCTCAGAAAGAAGAAGCGGAAGAAAAGGAGAGGAAAAAGATTGCCAGAAAAGAGAGCCTAGAAAATAAAAAGAACAACAAACCAGAAGTCAACCAGATAGCCAACAGTGACAACAAGGTTACAATTGATGACTATAGAGAAGAGGATGAAGACAAGGACCCCTATCCGCCTTGCGATGTGCCAGTAGGGGAAGAGGAAGAGGAAGAGGAGGAGGATGAACCTGAGGTTCCTGCCGGACCCCGTCCTCGAAGGATCTCGGAGTTGAACATGAAGGAAAAAATTGCCCCCATCCCTGAAGGGAGCGCTTTCTTCATTCTTAGCAAGACCAACCCGATCCGCGTAGGCTGCCACAAGCTCATCAACCACCACATCTTCACCAACCTCATCCTTGTCTTCATCATGCTGAGCAGCGCTGCCCTGGCCGCAGAGGACCCCATCCGCAGCCACTCCTTCCGGAACACGATACTGGGTTACTTTGACTATGCCTTCACAGCCATCTTTACTGTTGAGATCCTGTTGAAGATGACAACTTTTGGAGCTTTCCTCCACAAAGGGGCCTTCTGCAGGAACTACTTCAATTTGCTGGATATGCTGGTGGTTGGGGTGTCTCTGGTGTCATTTGGGATTCAATCCAGTGCCATCTCCGTTGTGAAGATTCTGAGGGTCTTAAGGGTCCTGCGTCCCCTCAGGGCCATCAACAGAGCAAAAGGACTTAAGCACGTGGTCCAGTGCGTCTTCGTGGCCATCCGGACCATCGGCAACATCATGATCGTCACCACCCTCCTGCAGTTCATGTTTGCCTGTATCGGGGTCCAGTTGTTCAAGGGGAAGTTCTATCGCTGTACGGATGAAGCCAAAAGTAACCCTGAAGAATGCAGGGGACTTTTCATCCTCTACAAGGATGGGGATGTTGACAGTCCTGTGGTCCGTGAACGGATCTGGCAAAACAGTGATTTCAACTTCGACAACGTCCTCTCTGCTATGATGGCGCTCTTCACAGTCTCCACGTTTGAGGGCTGGCCTGCGTTGCTGTATAAAGCCATCGACTCGAATGGAGAGAACATCGGCCCAATCTACAACCACCGCGTGGAGATCTCCATCTTCTTCATCATCTACATCATCATTGTAGCTTTCTTCATGATGAACATCTTTGTGGGCTTTGTCATCGTTACATTTCAGGAACAAGGAGAAAAAGAGTATAAGAACTGTGAGCTGGACAAAAATCAGCGTCAGTGTGTTGAATACGCCTTGAAAGCACGTCCCTTGCGGAGATACATCCCCAAAAACCCCTACCAGTACAAGTTCTGGTACGTGGTGAACTCTTCGCCTTTCGAATACATGATGTTTGTCCTCATCATGCTCAACACACTCTGCTTGGCCATGCAGCACTACGAGCAGTCCAAGATGTTCAATGATGCCATGGACATTCTGAACATGGTCTTCACCGGGGTGTTCACCGTCGAGATGGTTTTGAAAGTCATCGCATTTAAGCCTAAGGGGTATTTTAGTGACGCCTGGAACACGTTTGACTCCCTCATCGTAATCGGCAGCATTATAGACGTGGCCCTCAGCGAAGCAGACAACTCTGAAGAGAGCAATAGAATCTCCATCACCTTTTTCCGTCTTTTCCGAGTGATGCGATTGGTGAAGCTTCTCAGCAGGGGGGAAGGCATCCGGACATTGCTGTGGACTTTTATTAAGTCCTTTCAGGCGCTCCCGTATGTGGCCCTCCTCATAGCCATGCTGTTCTTCATCTATGCGGTCATTGGCATGCAGATGTTTGGGAAAGTTGCCATGAGAGATAACAACCAGATCAATAGGAACAATAACTTCCAGACGTTTCCCCAGGCGGTGCTGCTGCTCTTCAGGTGTGCAACAGGTGAGGCCTGGCAGGAGATCATGCTGGCCTGTCTCCCAGGGAAGCTCTGTGACCCTGAGTCAGATTACAACCCCGGGGAGGAGTATACATGTGGGAGCAACTTTGCCATTGTCTATTTCATCAGTTTTTACATGCTCTGTGCATTTCTGATCATCAATCTGTTTGTGGCTGTCATCATGGATAATTTCGACTATCTGACCCGGGACTGGTCTATTTTGGGGCCTCACCATTTAGATGAATTCAAAAGAATATGGTCAGAATATGACCCTGAGGCAAAGGGAAGGATAAAACACCTTGATGTGGTCACTCTGCTTCGACGCATCCAGCCTCCCCTGGGGTTTGGGAAGTTATGTCCACACAGGGTAGCGTGCAAGAGATTAGTTGCCATGAACATGCCTCTCAACAGTGACGGGACAGTCATGTTTAATGCAACCCTGTTTGCTTTGGTTCGAACGGCTCTTAAGATCAAGACCGAAGGGAACCTGGAGCAAGCTAATGAAGAACTTCGGGCTGTGATAAAGAAAATTTGGAAGAAAACCAGCATGAAATTACTTGACCAAGTTGTCCCTCCAGCTGGTGATGATGAGGTAACCGTGGGGAAGTTCTATGCCACTTTCCTGATACAGGACTACTTTAGGAAATTCAAGAAACGGAAAGAACAAGGACTGGTGGGAAAGTACCCTGCGAAGAACACCACAATTGCCCTACAGGCGGGATTAAGGACACTGCATGACATTGGGCCAGAAATCCGGCGTGCTATATCGTGTGATTTGCAAGATGACGAGCCTGAGGAAACAAAACGAGAAGAAGAAGATGATGTGTTCAAAAGAAATGGTGCCCTGCTTGGAAACCATGTCAATCATGTTAATAGTGATAGGAGAGATTCCCTTCAGCAGACCAATACCACCCACCGTCCCCTGCATGTCCAAAGGCCTTCAATTCCACCTGCAAGTGATACTGAGAAACCGCTGTTTCCTCCAGCAGGAAATTCGGTGTGTCATAACCATCATAACCATAATTCCATAGGAAAGCAAGTTCCCACCTCAACAAATGCCAATCTCAATAATGCCAATATGTCCAAAGCTGCCCATGGAAAGCGGCCCAGCATTGGGAACCTTGAGCATGTGTCTGAAAATGGGCATCATTCTTCCCACAAGCATGACCGGGAGCCTCAGAGAAGGTCCAGTGTGAAAAGGTCCGACTCAGGAGATGAACAGCTCCCAACTATTTGCCGGGAAGACCCAGAGATACATGGCTATTTCAGGGACCCCCACTGCTTGGGGGAGCAGGAGTATTTCAGTAGTGAGGAATGCTACGAGGATGACAGCTCGCCCACCTGGAGCAGGCAAAACTATGGCTACTACAGCAGATACCCAGGCAGAAACATCGACTCTGAGAGGCCCCGAGGCTACCATCATCCCCAAGGATTCTTGGAGGACGATGACTCGCCCGTTTGCTATGATTCACGGAGATCTCCAAGGAGACGCCTACTACCTCCCACCCCAGCATCCCACCGGAGATCCTCCTTCAACTTTGAGTGCCTGCGCCGGCAGAGCAGCCAGGAAGAGGTCCCGTCGTCTCCCATCTTCCCCCATCGCACGGCCCTGCCTCTGCATCTAATGCAGCAACAGATCATGGCAGTTGCCGGCCTAGATTCAAGTAAAGCCCAGAAGTACTCACCGAGTCACTCGACCCGGTCGTGGGCCACCCCTCCAGCAACCCCTCCCTACCGGGACTGGACACCGTGCTACACCCCCCTGATCCAAGTGGAGCAGTCAGAGGCCCTGGACCAGGTGAACGGCAGCCTGCCGTCCCTGCACCGCAGCTCCTGGTACACAGACGAGCCCGACATCTCCTACCGGACTTTCACACCAGCCAGCCTGACTGTCCCCAGCAGCTTCCGGAACAAAAACAGCGACAAGCAGAGGAGTGCGGACAGCTTGGTGGAGGCAGTCCTGATATCCGAAGGCTTGGGACGCTATGCAAGGGACCCAAAATTTGTGTCAGCAACAAAACACGAAATCGCTGATGCCTGTGACCTCACCATCGACGAGATGGAGAGTGCAGCCAGCACCCTGCTTAATGGGAACGTGCGTCCCCGAGCCAACGGGGATGTGGGCCCCCTCTCACACCGGCAGGACTATGAGCTACAGGACTTTGGTCCTGGCTACAGCGACGAAGAGCCAGACCCTGGGAGGGATGAGGAGGACCTGGCGGATGAAATGATATGCATCACCACCTTGTAG
ORF Protein Sequence MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTVLSWQAAIDAARQAKAAQTMSTSAPPPVGSLSQRKRQQYAKSKKQGNSSNSRPARALFCLSLNNPIRRACISIVEWKPFDIFILLAIFANCVALAIYIPFPEDDSNSTNHNLEKVEYAFLIIFTVETFLKIIAYGLLLHPNAYVRNGWNLLDFVIVIVGLFSVILEQLTKETEGGNHSSGKSGGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFIGKMHKTCFFADSDIVAEEDPAPCAFSGNGRQCTANGTECRSGWVGPNGGITNFDNFAFAMLTVFQCITMEGWTDVLYWMNDAMGFELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEEEGGEEGKRNTSMPTSETESVNTENVSGEGENRGCCGSLCQAISKSKLSRRWRRWNRFNRRRCRAAVKSVTFYWLVIVLVFLNTLTISSEHYNQPDWLTQIQDIANKVLLALFTCEMLVKMYSLGLQAYFVSLFNRFDCFVVCGGITETILVELEIMSPLGISVFRCVRLLRIFKVTRHWTSLSNLVASLLNSMKSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDETQTKRSTFDNFPQALLTVFQILTGEDWNAVMYDGIMAYGGPSSSGMIVCIYFIILFICGNYILLNVFLAIAVDNLADAESLNTAQKEEAEEKERKKIARKESLENKKNNKPEVNQIANSDNKVTIDDYREEDEDKDPYPPCDVPVGEEEEEEEEDEPEVPAGPRPRRISELNMKEKIAPIPEGSAFFILSKTNPIRVGCHKLINHHIFTNLILVFIMLSSAALAAEDPIRSHSFRNTILGYFDYAFTAIFTVEILLKMTTFGAFLHKGAFCRNYFNLLDMLVVGVSLVSFGIQSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQLFKGKFYRCTDEAKSNPEECRGLFILYKDGDVDSPVVRERIWQNSDFNFDNVLSAMMALFTVSTFEGWPALLYKAIDSNGENIGPIYNHRVEISIFFIIYIIIVAFFMMNIFVGFVIVTFQEQGEKEYKNCELDKNQRQCVEYALKARPLRRYIPKNPYQYKFWYVVNSSPFEYMMFVLIMLNTLCLAMQHYEQSKMFNDAMDILNMVFTGVFTVEMVLKVIAFKPKGYFSDAWNTFDSLIVIGSIIDVALSEADNSEESNRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIAMLFFIYAVIGMQMFGKVAMRDNNQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLACLPGKLCDPESDYNPGEEYTCGSNFAIVYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVMFNATLFALVRTALKIKTEGNLEQANEELRAVIKKIWKKTSMKLLDQVVPPAGDDEVTVGKFYATFLIQDYFRKFKKRKEQGLVGKYPAKNTTIALQAGLRTLHDIGPEIRRAISCDLQDDEPEETKREEEDDVFKRNGALLGNHVNHVNSDRRDSLQQTNTTHRPLHVQRPSIPPASDTEKPLFPPAGNSVCHNHHNHNSIGKQVPTSTNANLNNANMSKAAHGKRPSIGNLEHVSENGHHSSHKHDREPQRRSSVKRSDSGDEQLPTICREDPEIHGYFRDPHCLGEQEYFSSEECYEDDSSPTWSRQNYGYYSRYPGRNIDSERPRGYHHPQGFLEDDDSPVCYDSRRSPRRRLLPPTPASHRRSSFNFECLRRQSSQEEVPSSPIFPHRTALPLHLMQQQIMAVAGLDSSKAQKYSPSHSTRSWATPPATPPYRDWTPCYTPLIQVEQSEALDQVNGSLPSLHRSSWYTDEPDISYRTFTPASLTVPSSFRNKNSDKQRSADSLVEAVLISEGLGRYARDPKFVSATKHEIADACDLTIDEMESAASTLLNGNVRPRANGDVGPLSHRQDYELQDFGPGYSDEEPDPGRDEEDLADEMICITTL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T24793-Ab Anti-CAC1D/ CACNA1D/ CACH3 monoclonal antibody
    Target Antigen GM-Tg-g-T24793-Ag CACNA1D VLP (virus-like particle)
    ORF Viral Vector pGMAD001198 Human CACNA1D Adenovirus plasmid
    ORF Viral Vector vGMAD001198 Human CACNA1D Adenovirus particle


    Target information

    Target ID GM-T24793
    Target Name CACNA1D
    Gene ID 776, 12289, 693924, 29716, 101088394, 484724, 408013, 100051186
    Gene Symbol and Synonyms 8430418G19Rik,CACH3,CACN4,CACNA1D,CACNL1A2,Cav1.3,Cchl1a,CCHL1A2,D-LTCC,PASNA,SANDD
    Uniprot Accession Q01668
    Uniprot Entry Name CAC1D_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target
    Disease Not Available
    Gene Ensembl ENSG00000157388
    Target Classification Not Available

    Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, namely alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1D subunit. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2012]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.